

## Myanmar

### Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Myanmar							
<b>2. Vaccine grant number:</b>		16-MMR-08c-Y, 16-MMR-12b-X, 1721-MMR-12b-X, 1821-MMR-12d-X					
<b>3. Date of Decision Letter:</b>		30 September 2019					
<b>4. Date of the Partnership Framework Agreement:</b>		4 April 2014					
<b>5. Programme title:</b>		New Vaccine Support (NVS), Pneumococcal, Routine					
<b>6. Vaccine type:</b>		Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> PCV13, 4 dose(s) per vial, LIQUID							
<b>8. Programme Duration:<sup>1</sup></b>		2016-2021					
<b>9. Programme Budget (indicative):<sup>2</sup></b>		(subject to the terms of the Partnership Framework Agreement)					
	2016-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	36,677,135	6,953,500	7,667,000	-	-	-	51,297,635
<b>10. Vaccine introduction grant</b>							
<b>Approval</b>							
<b>Year</b>	<b>Grant Number</b>		<b>Amount (US\$)</b>				
2016	16-MMR-08c-Y		1,211,000				
<b>Disbursement</b>							
<b>Disbursement date</b>		<b>Amount (US\$)</b>					
08 February, 2016		607,638					
15 March, 2016		603,362					
<b>11. Product switch grant</b>							
<b>Not applicable</b>							
<b>12. Indicative Annual Amounts:<sup>3</sup></b>		(subject to the terms of the Partnership Framework Agreement)					
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2016-2019</b>	<b>2020</b>	<b>2021</b>				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

	Number of vaccine doses		2,176,900		-
	Annual Amounts (US\$)	36,677,135	6,953,500		-
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> Not applicable					
<b>15. Co-financing obligations:</b>					
According to the co-financing policy, the Country falls within the group:				Preparatory transition phase	
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>
Number of vaccine doses	268,600	377,200	-	-	-
Number of AD syringes	266,000	373,800	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	2,950	4,125	-	-	-
Value of vaccine doses (US\$)	778,374	1,093,862	-	-	-
Total co-financing payments (US\$) (including freight)	800,000	1,124,500	-	-	-
<b>16. Operational support for campaigns:</b>					
<b>Not applicable</b>					
<b>17. Additional Reporting Requirements:</b>					
					Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	<ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>				31 March 2020 15 May 2020 N/A
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.					To be agreed with Gavi Secretariat

<b>18. Financial clarifications:</b>	Country shall provide the following clarifications to Gavi*:
Not applicable	
* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
<b>19. Other conditions:</b>	
Not applicable	

*Signed by,*

**On behalf of Gavi**



Thabani Maphosa  
Managing Director, Country Programmes  
30 September 2019